GenMont Biotech (TPE:3164) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:3164 GenMont Biotech Inc TPE:3164
81 GF Score
Price NT$15.85
GF Value NT$21.07
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is GenMont Biotech Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GenMont Biotech  (TPE:3164) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


GenMont Biotech Cyclically Adjusted PB Ratio Related Terms


GenMont Biotech Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for GenMont Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenMont Biotech Cyclically Adjusted PB Ratio Chart

GenMont Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 1.23 1.25 1.03 0.94

GenMont Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.02 0.96 0.93 0.91 0.80

TPE:3164 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, GenMont Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMont Biotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GenMont Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GenMont Biotech's Cyclically Adjusted PB Ratio falls into.


TPE:3164
81GF Score
GenMont Biotech Inc TPE:3164
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenMont Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

GenMont Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, GenMont Biotech's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=16.616/333.9520*333.9520
=16.616

Current CPI (Jun. 2026) = 333.9520.

GenMont Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201609 16.745 241.428 23.162
201612 14.392 241.432 19.907
201703 14.361 243.801 19.671
201706 15.266 244.955 20.812
201709 15.451 246.819 20.906
201712 15.417 246.524 20.885
201803 15.505 249.554 20.749
201806 16.528 251.989 21.904
201809 17.256 252.439 22.828
201812 17.576 251.233 23.363
201903 18.172 254.202 23.873
201906 16.978 256.143 22.135
201909 17.155 256.759 22.313
201912 16.283 256.974 21.161
202003 16.281 258.115 21.065
202006 15.412 257.797 19.965
202009 16.877 260.280 21.654
202012 17.163 260.474 22.005
202103 17.422 264.877 21.965
202106 17.494 271.696 21.503
202109 17.042 274.310 20.747
202112 17.649 278.802 21.140
202203 18.318 287.504 21.277
202206 17.155 296.311 19.334
202209 17.305 296.808 19.471
202212 17.335 296.797 19.505
202303 16.763 301.836 18.547
202306 16.458 305.109 18.014
202309 17.007 307.789 18.453
202312 16.751 306.746 18.237
202403 16.783 312.332 17.945
202406 16.999 314.175 18.069
202409 17.181 315.301 18.197
202412 17.104 315.605 18.098
202503 16.639 319.799 17.375
202506 15.647 322.561 16.200
202509 16.202 324.800 16.659
202512 16.855 324.054 17.370
202603 16.346 330.213 16.531
202606 16.616 333.952 16.616

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is GenMont Biotech (TPE:3164) Overvalued in 2026?

Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued. The current stock price of NT$15.85 is trading 24.8% below its estimated GF Value™ of NT$21.07. GuruFocus considers GenMont Biotech to be Modestly Undervalued.

Key valuation signals for TPE:3164:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: NT$21.07 vs. price of NT$15.85 (24.8% below fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GenMont Biotech Business Description

Address No. 8 Nanke 7th Road, Tainan Science and Technology Park, Shanhua District, Tainan, TWN, 741014
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
81GF Score

Get the complete analysis for TPE:3164

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.85
Price
NT$21.07
GF Value